Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Símbolo de cotizaciónASRT
Nombre de la empresaAssertio Holdings Inc
Fecha de salida a bolsaFeb 12, 1997
Director ejecutivoReisenauer (Mark L)
Número de empleados58
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 12
Dirección100 S. Saunders Road
CiudadLAKE FOREST
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60045
Teléfono12244197106
Sitio Webhttps://www.assertiotx.com/
Símbolo de cotizaciónASRT
Fecha de salida a bolsaFeb 12, 1997
Director ejecutivoReisenauer (Mark L)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos